News Summaries

Gilead Teams Up with JD Health to Bring Breakthrough HIV Prevention to China in Record Time

At the end of June, Gilead’s long‑acting HIV pre‑exposure prophylaxis drug Lenacapavir received approval in Hainan’s Boao Lecheng International Medical Tourism Pilot Zone—just days after the U.S. FDA gave its green light. This near‑instant approval means Chinese patients can access the cutting‑edge HIV prevention pill almost simultaneously with their American counterparts, a first for the country. In October, the drug was administered in Boao, marking the world’s first use of Lenacapavir outside the United States and offering a powerful new option for people at risk of HIV in China. The momentum didn’t stop there. In August, Gilead’s Seladelpar, a treatment for the rare liver disorder primary biliary cholangitis, was cleared in Beijing’s Tianzhu Rare Disease Drug Guarantee Pilot Zone, thanks to the city’s fast‑track clinical import rules. Additional updates—including new indications for Tuodawei®, refreshed labeling for Bictuowei®, and a pediatric version of Bingtongsha®—show Gilead’s rapid expansion across virology, oncology and mycology. These breakthroughs reflect China’s recent push to open its market, tighten intellectual‑property protection, and speed up drug reviews. As Gilead’s China head Jin Fangqian put it, “Every improvement in the business environment has helped innovative medicines reach Chinese patients faster. We’re already seeing real benefits and will keep moving forward.”

Breakthrough: Chinese Researchers Find Brain Molecule Behind Fast‑Acting Depression Treatments

A team of Chinese scientists has uncovered why two of the most rapid‑acting depression therapies—ketamine and electroconvulsive therapy (ECT)—work so quickly. By monitoring live mice brains, they discovered that both treatments cause a sharp rise in adenosine, a natural “calming” molecule, in the medial prefrontal cortex and hippocampus. When the researchers blocked adenosine’s two main receptors (A1 and A2A), the antidepressant benefits of ketamine and ECT vanished, proving that adenosine signaling is the critical bridge. Building on this insight, the researchers proposed an “intermittent hypoxia intervention” (aIH) – a safe, controlled breathing technique that temporarily lowers oxygen levels to trigger the brain’s own adenosine release. In animal tests, aIH produced strong antidepressant effects without the side‑effects of drugs or electric shocks. The finding matters because conventional antidepressants often take weeks to lift mood, leaving many patients in limbo. A rapid, non‑invasive method that taps into the brain’s built‑in calming system could transform treatment for the hundreds of millions suffering from depression, especially those who don’t respond to standard pills. The study appears in Nature and points to a new, potentially game‑changing avenue for mental‑health care.

Pfizer’s China Strategy: From Test Site to Innovation Hub

In a candid interview, Pfizer’s China head Li Jinhui explains how the country has transformed from a peripheral participant in global drug trials to a core engine of innovation. Historically, multinational firms ran clinical studies elsewhere and only added Chinese sites after the global data were in hand. Today, China is being woven into the very design of trials, with Chinese investigators often serving as principal investigators (PIs) and even leading sub‑studies. This shift reflects two key trends: first, the growing confidence of global pharma in China’s data quality and regulatory environment; second, the rise of Chinese biopharma that is moving beyond generics to pioneering new molecular therapies. Li cites the lung‑cancer drug lorlatinib (Boren) as a showcase – Chinese experts led the China/Asia arm of the CROWN study, delivering five‑year data that showed 70 % of patients remained progression‑free. With a massive patient pool, China offers faster enrollment, accelerating the path from research to market. For Pfizer, this means quicker trials, larger data sets, and a stronger foothold in a market that is increasingly shaping worldwide drug development.